What Autotelic does

Autotelic is a privately held, for-profit biotechnology company founded in 2013 and headquartered in City of Industry, California. According to its stated description, the company applies therapeutic drug monitoring (TDM) — the measurement of drug concentrations in biological samples — to improve the development of therapeutics, presumably informing dosing, efficacy, and safety decisions during preclinical or clinical-stage development. The company operates with a staff of 11–50 employees and is led by CEO Vuong Trieu, founder Stephen Gibb, co-founder and Chief Business Officer Chulho Park, and Osmond D'Cruz as Director of Drug Safety.

The presence of a dedicated drug safety function and a CBO is consistent with a development-stage focus on therapeutic candidates, but no specific pipeline assets, indications, platform technology details, or clinical milestones are disclosed in available sources. The corporate website at autotelicinc.com is non-functional, displaying only empty Apache directory index pages with no product, pipeline, or company information. The technology stack, pricing model, distribution channels, customer segments, and GTM motion are not documented in the provided data.

Autotelic's external capital formation appears minimal based on disclosed information — a single recorded financing of $150,000 in December 2014 with unidentified investors, and no subsequent rounds, pharmaceutical partnerships, or licensing arrangements reported. No customers, pricing, or revenue figures are publicly disclosed. A 2026-dated source references an entity called 'Autotelic Ventures' co-leading a $5 million investment in the game studio Odd Meter, but the relationship between Autotelic Ventures and Autotelic (the biotech) is not clarified in available materials, leaving the overall business model, commercial trajectory, and entity structure materially unconfirmed.

Name

Autotelic

Website

https://autotelicinc.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Autotelic is a private biotech company founded in 2013 that applies therapeutic drug monitoring to enhance therapeutic drug development. The City of Industry, California-based firm employs 11–50 staff and has minimal disclosed external funding and no commercial products.

Ownership category

akta.pro rank

Product category

Drug Development Services

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)

akta.pro secondary industries

Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management (HLACAOAI), Toxicology & Therapeutic Drug Monitoring (HLAMADAG)

Keywords

• Therapeutic drug monitoring
• Drug development services
• Clinical pharmacology
• Biotech therapeutics
• Pharmacokinetic analysis

Headquarters

HQ city

City Of Industry

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Autotelic applies therapeutic drug monitoring (TDM) to support and enhance the development of therapeutics. The company's work centers on pharmacokinetic and pharmacodynamic assessment to inform dosing, safety, and efficacy decisions during drug development programs for partners in the pharmaceutical and biotechnology sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Therapeutic Drug Monitoring for Therapeutic Development Application of therapeutic drug monitoring (TDM) approaches — including pharmacokinetic analysis and drug-level measurement — to support the development, dosing optimization, and safety evaluation of new therapeutics. Targeted at pharmaceutical and biotechnology companies developing drug candidates.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves1 record

Expansion highlights2 records

Broad incumbents

• Eurofins Scientific: Eurofins is a global laboratory services group with significant pharmacokinetics, bioanalytical, and therapeutic drug monitoring capabilities serving pharma R&D. It competes with Autotelic by offering TDM and PK/PD assay work as part of a broad life sciences testing portfolio, often at greater scale.
• Labcorp Drug Development (formerly Covance): Labcorp's drug development arm provides central laboratory services including bioanalytical and TDM support for clinical trials. It is a broad incumbent that bundles TDM with full-service CRO capabilities, putting pricing pressure on specialists like Autotelic.
• Charles River Laboratories: Charles River offers bioanalytical, pharmacokinetic, and drug safety testing services that overlap with Autotelic's TDM-enabled drug development thesis. As a large preclinical CRO, it competes for the same pharma R&D budgets, particularly on the nonclinical and IND-enabling side.
• ICON plc (including PRA Health and MolecularMD): ICON is a global CRO with central labs and bioanalytical services supporting clinical pharmacology and TDM for trials. It is a broad incumbent that can offer sponsors an integrated lab + clinical operations package Autotelic cannot match.
• PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher, runs global central labs and bioanalytical services that include therapeutic drug monitoring for clinical trials. As a broad incumbent, it competes for the same pharma R&D TDM contracts as Autotelic.

Direct peers

• ARUP Laboratories: ARUP is a reference laboratory known for esoteric and specialized clinical testing, including therapeutic drug monitoring and toxicology. It is one of the closest direct comparables on TDM lab service capability, with a similar focus on complex, niche assay work for healthcare providers and researchers.
• Saladax Biomedical: Saladax develops and commercializes proprietary TDM assays (e.g., for chemotherapeutics and antipsychotics) used by hospitals and clinical trial sponsors. It is a direct niche peer, focused on commercializing TDM technology in much the same therapeutic-development orbit as Autotelic.
• Absorption Systems: Absorption Systems (now part of Eurofins) specialized in preclinical ADME/PK and bioanalytical services for drug development, including TDM-style assay work for small molecules and biologics. It is a closely aligned specialist peer serving similar biotech and pharma R&D customers.
• Alturas Analytics: Alturas Analytics is a bioanalytical CRO providing LC-MS/MS-based PK, TK, and bioequivalence assay services for drug development programs. It is a small specialist peer comparable to Autotelic in size and therapeutic-monitoring-focused value proposition.

Emerging players

• Syneos Health (clinical pharmacology unit): Syneos offers clinical pharmacology unit services with bioanalytical and PK sampling tightly integrated with early-phase trials. It is an emerging peer at the TDM-and-clinical-trial intersection, competing for the same outsourced drug-development work.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autotelic